Yahoo
LSE - Delayed Quote GBp

Shield Therapeutics plc (STX.L)

5.65 +0.15 (+2.73%)
At close: October 30 at 4:08:40 PM GMT
Chart Range Bar
Loading chart for STX.L
  • Previous Close 5.50
  • Open 5.48
  • Bid 5.50 x --
  • Ask 5.80 x --
  • Day's Range 5.40 - 5.60
  • 52 Week Range 3.70 - 12.50
  • Volume 1,148,746
  • Avg. Volume 2,289,612
  • Market Cap (intraday) 60.69M
  • Beta (5Y Monthly) 1.73
  • PE Ratio (TTM) --
  • EPS (TTM) -0.01
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 16.67

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.

www.shieldtherapeutics.com

61

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

STX.L
42.64%
FTSE 100 (^FTSE)
8.04%

1-Year Return

STX.L
16.91%
FTSE 100 (^FTSE)
9.94%

3-Year Return

STX.L
10.32%
FTSE 100 (^FTSE)
46.43%

5-Year Return

STX.L
84.69%
FTSE 100 (^FTSE)
48.25%

Analyst Insights

View More

Analyst Price Targets

12.00
16.67 Average
5.65 Current
23.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -17.69%

  • Return on Assets (ttm)

    -4.37%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    58.62M

  • Net Income Avi to Common (ttm)

    -10.37M

  • Diluted EPS (ttm)

    -0.01

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.35M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3.21M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: